Drug Profile
Research programme: neurodegenerative disorder therapeutics
Alternative Names: Azolol; ParkinolLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator ITL Pharma
- Class Polynucleotides
- Mechanism of Action Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Alzheimer's-disease in USA (Tablet)
- 28 Mar 2021 No recent reports of development identified for research development in Parkinson's-disease in USA (Tablet)
- 21 Feb 2017 Research programme: neurodegenerative disorder therapeutics is available for licensing as of 21 Feb 2017. http://www.itlpharmaceuticals.com/investors.html